Inogen Inc (NASDAQ:INGN) – Equities research analysts at Piper Jaffray Companies reduced their FY2019 earnings per share estimates for shares of Inogen in a research report issued on Tuesday, November 5th. Piper Jaffray Companies analyst J. Mckim now anticipates that the medical technology company will post earnings per share of $1.07 for the year, down from their prior estimate of $1.09. Piper Jaffray Companies has a “Overweight” rating and a $80.00 price objective on the stock. Piper Jaffray Companies also issued estimates for Inogen’s Q4 2019 earnings at $0.07 EPS, Q1 2020 earnings at $0.19 EPS, Q2 2020 earnings at $0.34 EPS, Q3 2020 earnings at $0.34 EPS, FY2020 earnings at $1.15 EPS, Q1 2021 earnings at $0.28 EPS, Q2 2021 earnings at $0.45 EPS, Q3 2021 earnings at $0.45 EPS and FY2021 earnings at $1.56 EPS.

Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, November 5th. The medical technology company reported $0.31 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.23 by $0.08. The firm had revenue of $91.76 million during the quarter, compared to analyst estimates of $91.65 million. Inogen had a net margin of 8.76% and a return on equity of 10.05%. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the business earned $0.73 EPS.

Other research analysts have also recently issued reports about the stock. ValuEngine raised shares of Inogen from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. Stifel Nicolaus cut shares of Inogen from a “buy” rating to a “hold” rating and lowered their target price for the stock from $85.00 to $48.00 in a report on Wednesday, August 7th. KeyCorp reaffirmed a “hold” rating on shares of Inogen in a report on Wednesday, August 7th. BidaskClub raised shares of Inogen from a “hold” rating to a “buy” rating in a report on Thursday. Finally, Needham & Company LLC raised shares of Inogen from a “hold” rating to a “buy” rating and set a $90.00 target price on the stock in a report on Wednesday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $82.00.

Shares of NASDAQ INGN opened at $69.07 on Friday. The firm has a market cap of $1.30 billion, a PE ratio of 30.03, a PEG ratio of 4.91 and a beta of 1.50. The company has a current ratio of 7.35, a quick ratio of 6.82 and a debt-to-equity ratio of 0.01. Inogen has a 1-year low of $41.19 and a 1-year high of $155.75. The company has a fifty day moving average price of $51.01 and a 200 day moving average price of $59.22.

In other news, Director Heath Lukatch purchased 2,000 shares of Inogen stock in a transaction that occurred on Thursday, August 15th. The shares were acquired at an average price of $43.01 per share, for a total transaction of $86,020.00. Following the transaction, the director now owns 5,481 shares of the company’s stock, valued at approximately $235,737.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Loren L. Mcfarland purchased 1,000 shares of Inogen stock in a transaction that occurred on Wednesday, September 4th. The shares were purchased at an average price of $42.93 per share, for a total transaction of $42,930.00. Following the transaction, the director now directly owns 4,481 shares in the company, valued at approximately $192,369.33. The disclosure for this purchase can be found here. 4.54% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of INGN. Advisor Group Inc. boosted its position in shares of Inogen by 71.4% during the 2nd quarter. Advisor Group Inc. now owns 461 shares of the medical technology company’s stock worth $31,000 after acquiring an additional 192 shares in the last quarter. TRUE Private Wealth Advisors acquired a new stake in shares of Inogen during the 2nd quarter worth approximately $66,000. Synovus Financial Corp acquired a new stake in shares of Inogen during the 3rd quarter worth approximately $77,000. Steward Partners Investment Advisory LLC boosted its position in shares of Inogen by 16.8% during the 3rd quarter. Steward Partners Investment Advisory LLC now owns 2,088 shares of the medical technology company’s stock worth $100,000 after acquiring an additional 300 shares in the last quarter. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Inogen during the 2nd quarter worth approximately $226,000.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading: Bid-Ask Spread

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.